WTA
PTCT icon

Washington Trust Advisors’s PTC Therapeutics PTCT Stock Holding History

Washington Trust Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-103
Closed -$2.31K – 694
2023
Q3 		$2.31K Sell
103
-41
-28% -$1.52K ﹤0.01% 633
2023
Q2 		$5.86K Hold
144
– – ﹤0.01% 525
2023
Q1 		$6.98K Hold
144
– – ﹤0.01% 553
2022
Q4 		$5.5K Hold
144
– – ﹤0.01% 588
2022
Q3 		$7K Hold
144
– – ﹤0.01% 659
2022
Q2 		$6K Hold
144
– – ﹤0.01% 723
2022
Q1 		$5K Hold
144
– – ﹤0.01% 826
2021
Q4 		$6K Buy
+144
New +$5.51K ﹤0.01% 827

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Washington Trust Advisors's PTCT Position: Q4 2023 in Review

Washington Trust Advisors sold out of PTC Therapeutics (PTCT) in Q4 2023, closing a stake of 103 shares — an estimated $2.31K sold.

Washington Trust Advisors first reported a position in PTCT in Q4 2021 and held it in 8 quarters. The position peaked at $7K in Q3 2022. 172 funds tracked by Wall St. Rank hold PTCT as of Q4 2023.

  • Washington Trust Advisors reported no remaining PTC Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Washington Trust Advisors sold 103 PTC Therapeutics shares in Q4 2023, an estimated $2.31K.
  • Washington Trust Advisors first reported a position in PTC Therapeutics in Q4 2021 and held it in 8 quarters.
  • Washington Trust Advisors's PTC Therapeutics position peaked at $7K in Q3 2022.
  • 172 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2023.

Based on Washington Trust Advisors's 13F filing for Q4 2023, filed 18 Jan 2024.